Adial Pharmaceuticals Files 8-K Report

Ticker: ADIL · Form: 8-K · Filed: Jan 13, 2025 · CIK: 1513525

Adial Pharmaceuticals, Inc. 8-K Filing Summary
FieldDetail
CompanyAdial Pharmaceuticals, Inc. (ADIL)
Form Type8-K
Filed DateJan 13, 2025
Risk Levellow
Pages2
Reading Time3 min
Sentimentneutral

Sentiment: neutral

Topics: 8-K, financial-statements, disclosure

TL;DR

ADIAL filed an 8-K on Jan 13, 2025, mostly financial docs. Nothing major revealed in this snippet.

AI Summary

On January 13, 2025, Adial Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating a routine update or disclosure rather than a major event. No specific financial figures or significant business developments were detailed in the provided excerpt.

Why It Matters

This filing indicates Adial Pharmaceuticals is meeting its reporting obligations with the SEC, which is standard practice for publicly traded companies. Investors can review the full filing for detailed financial information and exhibits.

Risk Assessment

Risk Level: low — The filing appears to be a routine disclosure of financial statements and exhibits, not indicating any immediate or significant risks.

Key Players & Entities

  • Adial Pharmaceuticals, Inc. (company) — Registrant
  • January 13, 2025 (date) — Date of Report
  • Delaware (jurisdiction) — State of Incorporation
  • Glen Allen, VA (location) — Principal Executive Offices

FAQ

What is the primary purpose of this 8-K filing by Adial Pharmaceuticals, Inc.?

The filing is primarily for Regulation FD Disclosure and to report Financial Statements and Exhibits, as indicated by the Item Information section.

On what date was this 8-K report filed?

The report was filed as of January 13, 2025.

What is the state of incorporation for Adial Pharmaceuticals, Inc.?

Adial Pharmaceuticals, Inc. is incorporated in Delaware.

What is the address of Adial Pharmaceuticals, Inc.'s principal executive offices?

The principal executive offices are located at 4870 Sadler Road, Ste 300, Glen Allen, VA 23060.

Does the provided excerpt detail any specific financial results or business developments?

No, the provided excerpt focuses on the form type, filing date, company information, and item information, but does not detail specific financial results or business developments.

Filing Stats: 664 words · 3 min read · ~2 pages · Grade level 11.6 · Accepted 2025-01-13 08:33:00

Filing Documents

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. Adial Pharmaceuticals, Inc. (the "Company") will be engaging in business development meetings over the next several weeks and has updated its business development presentation. A copy of the updated business development presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 7.01 and in the business development presentation attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed to be "filed" for purposes of Section 18 of the Securities Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 7.01 and in the business development presentation attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be incorporated by reference into any filing with the Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. The business development presentation attached as Exhibit 99.1 to this Current Report on Form 8-K includes "safe harbor" language pursuant to the Private Securities Litigation Reform Act of 1995, as amended, indicating that certain statements contained therein are "forward-looking" rather than historical. The Company undertakes no duty or obligation to update or revise the information contained in this Current Report on Form 8-K, although it may do so from time to time if its management believes it is appropriate. Any such updating may be made through the filing of other reports or documents with the Securities and Exchange Commission, through press releases or through other public disclosures.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits . (d) Exhibits. Exhibit No. Description 99.1 Business Development Presentation of Adial Pharmaceuticals, Inc., dated January 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: January 13, 2025 ADIAL PHARMACEUTICALS, INC. By: /s/ Cary J. Claiborne Name: Cary J. Claiborne Title: President and Chief Executive Officer 2

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.